Table 2.

Characteristics of marked metastases

	No. of marked metastases (n = 76)
Size of metastases (mm)
At diagnosis*	13·6(5·6)
At specific treatment†	7·6(7·2)
Marking techniques
Total no. of fiducial markers	89
Local anaesthesia (no. of patients)	24
Guiding technique
US
No. of CRLM	42
No. of fiducial markers	50
CEUS
No. of CRLM	13
No. of fiducial markers	15
CT
No. of CRLM	13
No. of fiducial markers	16
US–MRI
No. of CRLM	3
No. of fiducial markers	3
US–CT
No. of CRLM	5
No. of fiducial markers	5
Complications‡	4 (4)
Treatment of marked metastases
Thermoablation (21 patients)	43 (57)
RFA	32
MWA	10
Cryotherapy	1
Surgery (15 patients)	22 (29)
Metastasectomy	17
Segmentectomy	2
Major hepatectomy	3
Size at diagnosis (mm)*	15·8(6·9)
Size at surgery (mm)*	8·9(8·3)
Histological size (mm)*	11·9(7·1)
Pathological response (% viable cells)*	32(25)
Radiotherapy (1 patient)	1 (1)
No specific treatment (progression) (6 patients)	10 (13)

Values in parentheses are percentages unless indicated otherwise; values are

^*mean(s.d.) and

^†mean(s.d.) based on 37 patients (6 patients with 14 marked metastases were excluded because of progression).

^‡Total number of complications for total number of fiducial markers placed. CRLM, colorectal liver metastases; US, ultrasonography; CEUS, contrast‐enhanced ultrasonography; RFA, radiofrequency ablation; MWA, microwave ablation.